Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium

Antibody–drug conjugates (ADCs) combine the cytotoxicity of small-molecule drugs with antibody targeting. Due to their precise and powerful effect, they have become a new hotspot and an important trend in the research and development of anti-tumor antibody drugs. Every year, exciting new development...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Jiazheng, Wu, Siyu, Li, Rong, Jiang, Yuanhong, Zheng, Jianyi, Li, Zeyu, Li, Mingyang, Xin, Kerong, Guan, Xiaojiao, Li, Shijie, Chen, Xiaonan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385919/
https://www.ncbi.nlm.nih.gov/pubmed/37507780
http://dx.doi.org/10.1186/s13045-023-01475-9
Descripción
Sumario:Antibody–drug conjugates (ADCs) combine the cytotoxicity of small-molecule drugs with antibody targeting. Due to their precise and powerful effect, they have become a new hotspot and an important trend in the research and development of anti-tumor antibody drugs. Every year, exciting new developments and innovations in the treatment of urological tumors are introduced at the American Society of Clinical Oncology-Genitourinary (ASCO-GU) Cancers Symposium. In this article, we summarize some of the most impressive advances in new clinical trials and clinical data on ADCs in the 2023 ASCO-GU Cancers Symposium for the treatment of urothelial carcinoma.

Ejemplares similares